Physical activity levels in patients with melanoma during treatment with immune checkpoint inhibitors: Fitbit results from the CAMP-IT trial.

Abstract

e13610 Background: Wearable activity trackers offer possibilities to harness real-time patient data for predicting clinical outcomes in patients with cancer during treatment with immune checkpoint inhibitors (ICIs). As a first step towards this purpose, we aimed to assess the feasibility of using wearable activity trackers to objectively measure physical activity levels during the course of treatment. Methods: Patients with advanced melanoma, scheduled to receive treatment with ICIs were eligible to participate in the Comprehensive Ambulatory Monitoring Platform during ImmunoTherapy (CAMP-IT) trial. Participants were instructed to wear a Fitbit Versa 2.0 during waking hours for 12 weeks after start of immunotherapy. Feasibility of Fitbit use was assessed using predefined goals regarding compliance (> 75% participants with > 75% wear days) and acceptability (satisfaction score > 75%). Weekly averages of daily steps were calculated. A valid wear week was defined as a week with a minimum of 4 valid wear days (> 100 steps) including at least 1 weekend day. Linear mixed models were used to examine the changes in mean daily steps during 12 weeks after treatment initiation. We currently analyzed data of the first 30 of the 50 patients that will be included in the trial. Results: Of the 30 patients that were currently included 57% was female and mean age was 57,3 (SD 9,7). Forty percent had metastatic disease, and 30% received treatment with combination ICI therapy. Ninety-six percent of patients was compliant with Fitbit use. Moreover, Fitbit use was rated as satisfactory by 86% of patients. Mean steps per day in week 1 was 6728 (SD 3405). Mean daily steps per week did not change significantly over time during the observation period (b = -13,3 (95% CI: -85,7 - 59,1); p = 0.72). Conclusions: This is the first prospective study that reports on the use of consumer-grade wearable activity trackers to objectively measure physical activity in advanced melanoma patients during treatment with ICIs. Our results suggest that the use of wearable activity trackers in these patients is feasible and that treatment with ICI does not impact physical activity levels during the first 12 weeks. Future research should investigate whether our results hold true for specific subgroups (e.g., patients that receive combination ICI therapy). Clinical trial information: NL8827.